|
Market Closed -
Nasdaq
00:00:00 11/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 109.96 USD | -2.15% |
|
-7.25% | +68.39% |
Company Valuation: Monopar Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 40.42 | 30.62 | 5.058 | 134.2 | 436.4 | 738.1 | - | - |
| Change | - | -24.23% | -83.48% | 2,552.79% | 225.25% | 69.14% | - | - |
| Enterprise Value (EV) 1 | 40.42 | 30.62 | 5.058 | 134.2 | 296 | 619.3 | 593.5 | 569.9 |
| Change | - | -24.23% | -83.48% | 2,552.79% | 120.6% | 109.25% | -4.17% | -3.97% |
| P/E | -4.4x | -2.86x | -0.56x | -5.35x | -35.3x | -44x | -43.9x | -36.7x |
| PBR | - | - | - | - | 3.17x | 6.97x | 8.24x | 7.82x |
| PEG | - | -0.2x | 0x | -0.2x | 0.6x | -1.3x | -126.84x | -1.9x |
| Capitalization / Revenue | - | - | - | - | - | - | 26.1x | 8.71x |
| EV / Revenue | - | - | - | - | - | - | 21x | 6.73x |
| EV / EBITDA | - | - | - | - | -17.7x | -15.2x | -23.9x | -212x |
| EV / EBIT | -4.43x | -2.91x | -0.57x | -8.3x | -17.7x | -22.7x | -14.2x | -20.1x |
| EV / FCF | - | - | - | -20.9x | -24.3x | -24.7x | -29.4x | -74.7x |
| FCF Yield | - | - | - | -4.77% | -4.12% | -4.05% | -3.41% | -1.34% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.65 | -4.15 | -3.05 | -4.11 | -1.85 | -2.496 | -2.505 | -2.996 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 28.26 | 84.73 |
| EBITDA 1 | - | - | - | - | -16.7 | -40.77 | -24.81 | -2.694 |
| EBIT 1 | -9.127 | -10.54 | -8.831 | -16.16 | -16.7 | -27.29 | -41.79 | -28.39 |
| Net income 1 | -9.103 | -10.52 | -8.402 | -15.6 | -13.72 | -21.46 | -26.62 | -29.6 |
| Net Debt 1 | - | - | - | - | -140.4 | -118.8 | -144.6 | -168.1 |
| Reference price 2 | 16.05 | 11.85 | 1.70 | 22.00 | 65.30 | 109.96 | 109.96 | 109.96 |
| Nbr of stocks (in thousands) | 2,518 | 2,584 | 2,973 | 6,098 | 6,683 | 6,712 | - | - |
| Announcement Date | 24/03/22 | 23/03/23 | 28/03/24 | 31/03/25 | 27/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -45.02x | - | -15.59x | - | 738M | |
| 31.44x | 5.66x | 16.96x | 1.03% | 46.05B | |
| -21.25x | 245.77x | -22.82x | -.--% | 43.59B | |
| 33.09x | 3.22x | 13.91x | -.--% | 42.35B | |
| 45.98x | 5.31x | 29.05x | -.--% | 38.86B | |
| 27.78x | 8.36x | 21.2x | 0.41% | 32.24B | |
| 33.34x | 5.46x | 24.79x | -.--% | 16.28B | |
| 23.65x | 2.07x | 8.96x | 1.13% | 14.32B | |
| 74.46x | 3.94x | 15.27x | -.--% | 13.03B | |
| Average | 22.61x | 34.97x | 10.19x | 0.32% | 27.5B | |
| Weighted average by Cap. | 25.96x | 47.65x | 11.75x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MNPR Stock
- Valuation Monopar Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
